文献速递核素与放射性配体治疗肿瘤 PET/CT放射性药物与辐射防护

[177Lu]Lu-DOTAGA.Glu.(FAPi)2治疗肉瘤患者的疗效与安全性

Efficacy and Safety of [177Lu]Lu-DOTAGA.Glu.(FAPi)2 Therapy in Patients with Sarcoma.
PubMed 文献 · J Nucl Med · 2025-10-01

这项回顾性分析纳入10例组织学确诊的肉瘤患者,接受[177Lu]Lu-DOTAGA.Glu.(FAPi)2中位累积活度17.5 GBq(范围6.3-55.5 GBq),中位3个治疗周期(范围1-6个周期)。PERCIST评估部分缓解率33.3%,疾病控制率50%;RECIST评估无客观缓解,疾病控制率22.3%。中位无进展生存期约5个月(95%CI 2.9-7.1个月),中位总生存期8个月(95%CI 5.5-10.5个月),总体耐受性良好。

要点

  • 10例肉瘤患者接受[177Lu]Lu-DOTAGA.Glu.(FAPi)2治疗,中位累积活度17.5 GBq,中位3个周期。
  • PERCIST评估部分缓解率33.3%、疾病控制率50%;RECIST评估无客观缓解、疾病控制率22.3%。
  • 中位无进展生存期约5个月(95%CI 2.9-7.1个月),中位总生存期8个月(95%CI 5.5-10.5个月)。

核心结论

  • [177Lu]Lu-DOTAGA.Glu.(FAPi)2在肉瘤患者中显示出临床抗肿瘤活性,安全性可控。
  • 作者认为需要更大规模队列和联合治疗研究来优化疗效并改善结局。

研究设计与样本

  • 回顾性分析,纳入10例组织学确诊的肉瘤患者。
  • 患者接受[177Lu]Lu-DOTAGA.Glu.(FAPi)2中位累积活度17.5 GBq(范围6.3-55.5 GBq),中位3个治疗周期(范围1-6个周期)。
  • 6例患者采用PERCIST评估疗效,9例患者采用RECIST 1.1评估疗效。
  • 主要终点为疾病控制率,定义为完全缓解、部分缓解或疾病稳定,通过形态学、分子或临床标准评估;次要终点包括无进展生存期、总生存期和安全性。

主要发现

  • [177Lu]Lu-DOTAGA.Glu.(FAPi)2总体耐受性良好。
  • PERCIST评估显示33.3%的患者达到部分缓解;RECIST评估未观察到客观缓解。
  • PERCIST评估的疾病控制率为50%,RECIST评估的疾病控制率为22.3%。
  • 7例患者记录到疾病进展,其中3例死于疾病相关并发症。
  • 中位无进展生存期约5个月(95%CI 2.9-7.1个月),中位总生存期8个月(95%CI 5.5-10.5个月)。

局限性

  • 原文结论指出需要更大规模队列和联合治疗研究来优化疗效并改善结局。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The aim of this study was to evaluate the efficacy and safety of [177Lu]Lu-DOTAGA.Glu.(FAPi)2 therapy in patients with sarcoma, a cohort of individuals with limited treatment options and significant disease burden. Methods: This retrospective analysis involved 10 patients with histologically confirmed sarcoma. Patients received a median cumulative activity of 17.5 GBq (range, 6.3-55.5 GBq) of [177Lu]Lu-DOTAGA.Glu.(FAPi)2 administered over a median of 3 treatment cycles (range, 1-6 cycles). Patient responses were assessed using PERCIST in 6 patients and RECIST 1.1 in 9 patients. The primary endpoint was the disease control rate, defined as complete response, partial response, or stable disease, evaluated through morphologic, molecular, or clinical criteria. Secondary endpoints included progression-free survival, overall survival, and safety. Results: [177Lu]Lu-DOTAGA.Glu.(FAPi)2 was generally well tolerated. Response assessment using PERCIST indicated a partial response in 33.3% of patients, whereas no objective response was observed in the response assessed with RECIST. Disease control rates were 50% and 22.3% with PERCIST and RECIST, respectively. Disease progression was documented in 7 patients, 3 of whom succumbed to disease-related complications. The median progression-free survival was approximately 5 mo (95% CI, 2.9-7.1 mo), and the median overall survival was 8 mo (95% CI, 5.5-10.5 mo). Conclusion: [177Lu]Lu-DOTAGA.Glu.(FAPi)2 demonstrated clinical antitumor activity with a manageable safety profile in patients with sarcoma. Further studies with larger cohorts and combination therapies are warranted to optimize therapeutic efficacy and improve outcomes.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Ballal S, Sakir M, Chandekar KR, et al. Efficacy and Safety of [177Lu]Lu-DOTAGA.Glu.(FAPi)2 Therapy in Patients with Sarcoma. J Nucl Med. 2025. PMID: 40841150. doi:10.2967/jnumed.125.270186

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。